News & Events

Below are some links to news stories, fund-raising events, latest medical developments in the treatment of prostate cancer and much more:

01/05/2024 – TRANSFORM Trial

“The £42 million TRANSFORM trial, the biggest prostate cancer screening trial in 20 years, could save the lives of thousands of men each year.” – Prostate Cancer UK

Prostate Cancer UK is launching this new initiative – the TRANSFORM trial – to improve the way we screen men for prostate cancer.

It is the most ambitious trial in prostate cancer screening for 20 years and has been put together by the NHS, the National Institute for Health and Care Research (NIHR) and the UK Government. Funding has also come from the UK Government, Movember and the Freddie Green and Family Charitable Foundation and others.

The TRANSFORM trial, will target hundreds of thousands of men for screening. 12,000 men die of prostate cancer each year, it is the most common cancer in the UK and yet doesn’t have a screening programme.

More here.

16/10/2023 – Variable Radiotherapy

“We are pleased about recent announcements about prostate cancer variable radiotherapy which has less side effects like impotence and the need to have hormone replacement therapy treatment.” – PCW &UK

Men undergoing treatment for prostate cancer could be safely given far less radiotherapy, a major trial has found.

Doses can be cut by three-quarters meaning five higher doses is enough, instead of the 20 or so given now.

The international trial involved nearly 900 men with medium-risk prostate cancer that had not spread.

Lead researcher Prof Nicholas van As from the Royal Marsden Hospital said the results were “outstanding” and “fantastic” for patients.

Prostate Cancer UK said the finding had the potential to save time and money for the NHS, while still giving men the best outcomes.

More here.

14/11/2022 – Learning From The Masters

The Imperial Prostate masterclass on Focal Therapy took place last week at Imperial College – refreshingly for the first time in person since 2019, and returning bigger and better.

The faculty – both resident and visiting – is undeniably a collective of world leaders and pioneers in imaging and focal treatments for prostate cancer.

TFTC Consultant Urologist Raj Nigam presented a session on MR/US fusion biopsies of the prostate, with an emphasis on the critical role that clear, detailed radiological reporting plays in  successful precision biopsying. Raj was supported by TFTC radiological consultant Dr Clare Allen in demonstrating how state-of-the-art contouring of a patient’s MR imaging provides the essential roadmap for precision biopsying of the prostate.

More here.

2/12/2019 – Prostate cancer: AI pathologist used to help diagnosis

Artificial intelligence could improve cancer diagnosis and help save lives, a senior doctor has claimed.  Betsi Cadwaladr University Health Board has rolled out an “AI pathologist” to help test men for prostate cancer.

The software uses algorithms to detect cancer, and is the first to be used within a clinical setting in the UK.  Of 105 patients tested in north Wales so far, it has correctly diagnosed every one.  Researchers are seeing if they can use a similar technique to diagnose breast cancer.

More here.

24/12/19 – FDA Approves New Drug

December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).

PCF funded the initial synthesis of enzalutamide at UCLA by chemist Michael Jung, PhD, in collaboration with prostate cancer physician-scientist Charles Sawyers, MD (now at Memorial Sloan Kettering Cancer Center).

mHSPC refers to men whose prostate cancer has spread to areas of the body outside of the prostate itself, and who are responsive to testosterone-lowering agents.  This may refer to men who have had prior surgery or radiation and recurred, or men who were initially diagnosed with disease that was already metastatic (outside the prostate).  Patients who are “hormone-sensitive” may have previously received androgen deprivation therapy (ADT) for a certain amount of time, but their cancer has not yet developed resistance to ADT.

More here.

19/6/2018 – Wales ‘behind’ in technology to detect prostate cancer

A father-of-four who survived prostate cancer has said he is “fortunate” to be alive after an MRI scan spotted the disease before it developed.  Sion Brynach, from Cardiff, is now calling for more men to get access to a pre-biopsy scan to give them more of a chance at life.

It comes as a new report shows Wales is lagging behind in access to mpMRI scans – which can detect the disease better.  The Welsh Government said the use of mpMRI was under review.

The Multiparametic MRI (mpMRI) scan, which is done before a biopsy, is able to boost detection of prostate cancer.  In England, an NHS trial is under way to cut prostate cancer diagnosis times from six weeks to a matter of days using the scan.  But in Wales only three out of seven Welsh health boards provide the scan, as it is not currently recommended by the National Institute of Clinical Excellence (NICE).

More here.

19/2/18 – BBC Radio Wales

Nick Phillips was talking on the Jason Mohammed show about cancer waiting times from diagnosis to treatment.

30/1/18 – GTFM Pontypridd

Nick Phillips appeared on the local valleys radio show talking about Prostate Cancer, and the campaign he is running about the need to get checked.

17/9/16 – Charity Gig – ‘The Poptarts’

The Rose and Crown pub, Pontypridd are hosting a charity night to raise money for Prostate Cancer UK. Please contact us for more details.

29/7/16 to 11/8/16 – Wales Trails
Wales Trails_tshirt_front

Welsh writer Dave Lewis is cycling 600+ miles around Wales this summer to raise funds for Prostate Cancer UK. You can follow his progress and help support him by visiting his JustGiving page.
Read more

If you have any news, links, content we could add please email us at the usual address.